Biologics Safety Testing Market Size, Share, By Offering [Services (Sterility Testing Services, Mycoplasma Testing Services, Endotoxin Testing Services, Bioburden Testing Services, Virus Safety Testing Services, and Others), Consumables (Reagents and Kits), and Instruments], Application (Vaccines & Therapeutics, Cellular & Gene Therapy, Blood & Blood-based Therapy, and Others), End Users (Pharmaceutical & Biopharmaceutical Companies, Research Institutions, and Others) and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the target market is expected to increase at a rate of USD 13.2 Billion.
• Biologics Safety Testing Market size was worth at USD 4.5 Billion in 2024.
• The market is expanding at a CAGR 11.5%.

Biologics safety testing is the process of evaluating the safety of biologic products before it is approved for human use.  Biologics include, components, such as vaccines, gene therapies, monoclonal antibodies, and cell based therapies. The goal of biologics safety testing is to verify that products are free from harmful contaminants, pathogens, and other potential risks that could affect human health. It involves clinical trials, sterility and stability testing, ongoing monitoring and others. It is regulated by regulatory agencies, such as FDA, EMA, and the World Health Organization. This organization sets guidelines to ensure safety, efficacy, and quality standards of biologic products.

The increase approval of biologic drugs, rises the demand for safety testing services to ensure these therapies are safe for human use, resulting to drive target market growth. The growing burden of chronic diseases, and the expansion of biopharmaceutical testing capabilities, is anticipated to drive biologics safety testing market share. Increasing focus on personalized medicine, rapid growth in biotechnology & pharmaceutical industries, and rising demand for biologic products, are expected to propel growth of target market.

Integration of artificial intelligence, machine learning for more accurate results, advancement in gene, cell therapies, development of biosimilar, and increasing investment in animal-free testing is projected to growth of biologics safety testing market size. Growing focus on development of advanced testing technologies, is fuel the expansion of target market share.

Impact of AI in Biologics Safety Testing Market:

• Artificial Intelligence (AI) can significantly speed up analytical testing process by reducing the time takes to process test results. Machine learning algorithms can analyze patterns in complex data and improves the accuracy, and precision of stability tests, by reducing human errors. AI can identify novel biomarkers linked to safety issues, which is crucial for monitoring patient response to biologic drugs.

Key Drivers of Target Market:

Expansion of Biopharmaceutical Testing Capabilities is anticipated to Rise Market Growth

The increasing demand for high-quality testing solutions to ensure safety, efficacy, and regulatory compliance of biologics and pharmaceutical products, leads to the expansion of safety testing capabilities, to meet need of testing services. The growing adoption of cell and gene therapies to treat rare diseases, rises the demand for biopharmaceutical testing capabilities. The rapid expansion or development of CGT products require safety testing methods to ensure novel drug, or vaccine is free from harmful contaminants. The growing adoption of advanced technologies, such as PCR-based testing methods for the detection of viral infectants help to improve efficiency of testing processes. The expansion of testing capabilities, gives solution for more accurate methods to handle biologic manufacturing, is anticipated to drive biologics safety testing market growth.  

• For instance, according to article published by, Sage Publications in August 2024, this article states that, the biologics safety testing market is growing rapidly due to the increasing need for comprehensive testing in the production of biologics, including vaccines, gene and cell therapy (CGT) products, and other biologics. These test are crucial to ensure that raw materials, in processed bulk materials, and final products are free from contamination agents. The gene and cell therapies (CGT) are rapidly used to treat rare diseases, are mostly contaminated with mycoplasmas and replication-competent viruses. The mycoplasma contamination rates in cell cultures used for biologic production were reported to 0.4% to 6.7% in a study conducted by commercial testing laboratories. To ensure safety of biologics, regulatory bodies set guidelines for the detection and control o contaminations during manufacturing of biologics.

Restraints:

High Costs of Advanced Testing Technologies Disrupt the Target Market Growth

The adoption of advanced testing services, such as AI-driven platforms, and high-throughput testing, comes with high initial investment. For small and medium companies, the initial investment for state-of-the-art equipment, software and training program may be difficult, resulting to disrupt the target market growth.

• Counterbalance Statements: Technological advancement decreases costs of innovation progress, making these equipment affordable in the future. Many companies are adopting outsource testing services to specialized providers, collaborating with manufacturer to reduce initial setup cost, is anticipated to drive biologics safety testing market growth.

Opportunities & Market Trends:

Rising Funding for Animal-free Testing Solutions Surge Market Growth

The increasing global awareness and demand for ethical alternative to animal testing, many pharmaceutical companies are focusing on animal-free alternatives. Governments and regulatory bodies are straight polices for the animal testing, resulting rises focus in AI-driven platforms and human MicroPhysiological Systems (hMPS). Animal-free testing solutions powered by AI algorithms can provide more accurate and predicative results, as compared to traditional methods. Thus, biotechnology and pharmaceutical companies, are rising funding to streamline their product pipeline to ensure safety testing of drugs and vaccines, resulting to drive biologics safety testing market share.

The biologics safety testing market is segmented into offering, application, end-user and region.

By Offering:

Based on offering, the target market is divided into services, consumables, and instruments. Services segment hold the largest biologics safety testing market share, due to it is critical to ensure the safety, efficacy, and compliance of biologic products, such as vaccines, therapeutics and gene therapies. Regulatory bodies such as FDA, EMA and WHO are stringent guidelines for biologics safety products for human use, this includes, sterility testing, mycoplasma testing, endotoxin testing and others, resulting to drive segment’s growth in biologics safety testing market share.

Consumable is the second dominant segment in biologics safety testing market. It is essential for various biologics safety tests, the growth in biologics manufacturing, increasing focus on drug safety and rising demand of consumables in biologics safety testing, is expected to propel segment’s expansion in target market.

By Application:

On the basis of application, biologics safety testing market is segmented into, vaccines & therapeutics, cellular & gene therapy, blood & blood-based therapy, and others. Vaccines and therapeutics segment dominates in target market, due to rising demand for vaccines to treat various diseases, which requires safety testing of vaccines before human use. The demand for therapeutic biologics, such as monoclonal antibodies, recombinant proteins, and drugs, require safety testing services to ensure these products are effective and safe for patient, leading to growth of segment in biologics safety testing market.

Cellular and gene therapy segment hold the second largest biologics safety testing market share.  The target market growth is driven by, increasing approval of gene & cell-based therapies, growing clinical trials and commercialization of CGT, which rises the demand for biologics safety testing.

By End-user:

Pharmaceutical & biopharmaceutical companies, research institutions, and others are the categorized by the end-user for biologics safety testing market. Pharmaceutical and biopharmaceutical companies segment dominates in target market, due to growing demand for safety testing services. These companies require various stages of drug development, discovery, blood & blood-based therapy, regulatory compliance to ensure the safety, efficacy and quality of drugs, vaccines, resulting to drive biologics safety testing market share.

 Regional Insights:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.  

North America: This region hold the largest share of 36.61% in biologics safety testing market. The presence of major biopharmaceutical companies, contract research organization, and regulatory bodies, are focused to ensure safe delivery of drugs to human use, resulting to drive target market growth. Technological innovations in biologic testing, with increasing investment in AI automation, and high-throughput testing technologies, is anticipated to region growth in biologics safety testing market share.

• U.S. Biologics Safety Testing Market Insights:

In the biologics safety testing market, U.S. has experienced significant growth in recent years and is projected to continue expanding. The target market share is driven by, presence of major biopharmaceutical companies, regulatory bodies plays crucial role in ensuring safety standards, growing investments in biotech R&D and biologic manufacturing.

Asia Pacific: This is the expected to fastest growing region in target market, due to increasing investments by companies to develop advanced safety services. Rising burden of diseases, expanding cell & gene therapies, and technological advancement in high-quality endotoxin testing, is projected to drive region growth in biologics safety testing market size.

• China Biologics Safety Testing Market Insights:

China hold the highest share in Asia Pacific region for the biologics safety testing market. The rapidly growing pharmaceutical, biotechnology industry, growing focus on manufacturing and development of biologics, including cell and gene therapies, and increasing investment in biologics safety testing, is anticipated to drive target market growth.

Europe: This region is growing at highest share in biologics safety testing market. The presence of strong regulatory bodies, which ensure biologic safety standards, growing biopharmaceutical companies developing novel biologic therapies, and advancement in gene therapies, with increased focus in biosafety & contamination detection, is expected to fuel region growth biologics safety testing market.

• Germany Biologics Safety Testing Market Insights:

Germany is the dominant country in Europe region. The target market growth is attributed by several factors, such as increasing focus on drug development, clinical trials, presence of biologics manufactures, and increasing demand of novel drug development, including gene therapies and vaccines.

Biologics Safety Testing Market Report Scope:

Attribute	Details
Market Size 2025	USD 4.9 Billion
Projected Market Size 2035	USD 13.2 Billion
CAGR Growth Rate	11.5% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Billion & CAGR from 2025 to 2035
Regional scope	North America - U.S., and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India Japan, Australia Indonesia Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa – GCC, Israel South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Offering:

• Services
  • Sterility Testing Services
  • Mycoplasma Testing Services
  • Endotoxin Testing Services
  • Bioburden Testing Services
  • Virus Safety Testing Services
  • Others
• Consumables
  • Reagents and Kits
• Instruments

By Application:

• Vaccines & Therapeutics
• Cellular & Gene Therapy
• Blood & Blood-based Therapy
• Others

By End-user:

• Pharmaceutical & Biopharmaceutical Companies
• Research Institutions
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Abcam Limited, PathogenDx, SGS Société Générale de Surveillance SA, and others are the key players operating in biologics safety testing market. The growing demand for advanced medical solutions, thus companies are adopting strategies, such as advanced protocol for biologics safety testing, agreement, higher investments and collaboration with other organization, is projected to drive biologics safety testing market growth.

Biologics Safety Testing Market Companies:

• Abcam Limited
• PathogenDx
• SGS Société Générale de Surveillance SA.
• Thermo Fisher Scientific, Inc.
• Boehringer Ingelheim International GmbH
• Sartorius AG
• Wuxi AppTec
• Lonza
• Merck KGaA
• Charles River Laboratories
• Invetech
• Eurofins Scientific
• Samsung Biologics
• BIOMÉRIEUX
• Microtrac Retsch GmbH

View an Additional List of Companies in the Biologics Safety Testing Market

• In January 2024, Eurofins CDMO Alphora Inc., has successfully completed its pilot-scale biologics development facility. This facility, aimed to develop and scale monoclonal antibodies (mAbs), and other mammalian-based therapeutic proteins. This facility aimed to offer GMP QC testing, QMP Cell-based assay and scale-up capacity for pre-clinical and phase I trials.  The Amber 250 and BioProfile FLEX2 Automated Cell Culture Analyzer were cutting-edge tools that facilitate precise monitoring and optimization of cell culture conditions. This technology enabled efficient, high-quality bioprocessing, which ensure consistent production of biologic drugs.
• In October 2024, SGS announced expansion of new capacity and capabilities at the Center of Excellence in Lincolnshire, Illinois, for the analytical services for biologics and complex drug testing. This center aimed to provide services such as, early cell bank safety assessment, product characterization, method development, raw material testing and final product release. These enhancements aimed to facilitate analytical testing in both the discovery and commercial stages in biopharmaceutical network, and provide delivery of comprehensive, streamlined, and flexible service model to client.
• In July 2024, The USP Microbiology Expert Committee approved the Bacterial Endotoxins Test Using Recombinant Reagents. This approval for the use of non-animal derived regents for endotoxin testing, to the United States Pharmacopeia–National Formulary (USP–NF). Endotoxin testing is critical step to ensure the quality and safety of many sterile pharmaceutical products, and incorporate it into quality testing.
• In February 2024, Thermo Fisher Scientific, Inc., expand good manufacturing practices (GMP) laboratory services with biosafety testing capabilities by mycoplasma testing service. This new services, aimed to offer analytical testing service, to ensure biopharmaceutical products are free from contaminants, to deliver safe medications for patients. 

• In April 2021, Lonza announced an expansion of PyroTec PRO Automated Robotic Solution for endotoxin testing. The new PyroWave Reader, designed specifically for use with the sustainable PyroGene Recombinant Factor C (rFC) Assay. This brings a test type option to the platform, which allowed QC microbiologists to choose the endotoxin test method based on testing needs. The integration of the PyroWave XM Fluorescent Reader and the PyroGene Recombinant Factor C (rFC) Assay added new testing capabilities to the platform, which enhanced its versatility and automation.

Analyst View:

Biologics safety testing market is rapidly growing due to advancements in technology, regulatory requirements, and the growing demand for high-quality biologics testing. A pharmaceutical and biopharmaceutical companies investing to expand their capabilities for safety testing, and animal-free testing solutions, is anticipated to drive biologics safety testing market share.

More Related Reports

Subcutaneous Biologics Market
Wound Care Biologics Market
Biologics CDMO Market
Food Safety Testing Market
Safety Prefilled Syringe Market

Company Name	Thermo Fisher Scientific, Inc.
Headquarter	Waltham, Massachusetts
CEO	Marc N. Casper
Employee Count (2024)	125,000 employees